Blueprint Medicines Corp

NASDAQ:BPMC   11:10:37 AM EDT
56.35
+0.41 (+0.73%)
Earnings Announcements

Blueprint Medicines Reports First Quarter 2022 Results

Published: 05/03/2022 13:26 GMT
Blueprint Medicines Corp (BPMC) - Blueprint Medicines Reports First Quarter 2022 Results.
Q1 Loss per Share $1.79.
Q1 Revenue $62.7 Million.
On Track to Report Topline Data for Registration-enabling Pioneer Trial of Ayvakit in Non-advanced Sm in Late Summer 2022.
Anticipate Approximately $180 to $200 Million in Total Net Revenues in 2022.
Q1 Earnings per Share View $-1.86, Revenue View $38.7 Million -- Refinitiv Ibes Data (analyst estimates).
FY2022 Revenue View $192.3 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $36.52 Million
Adjusted EPS is expected to be -$2.22

Next Quarter Revenue Guidance is expected to be $43.37 Million
Next Quarter EPS Guidance is expected to be -$2.17

More details on our Analysts Page.